Du premier souffle aux années dorées : La prévention du virus syncytial chez les nourrissons et les personnes âgées
Résumé
Le virus respiratoire syncytial (VRS) est responsable de l’une des infections respiratoires les plus courantes observées en soins primaires. Bien que beaucoup considèrent le VRS comme un « simple rhume », il constitue une menace sérieuse pour la santé de certaines populations, notamment les enfants, en particulier les nourrissons âgés de 6 mois ou moins, les personnes présentant des affections concomitantes et les personnes âgées. Avec le nombre croissant d’options permettant de réduire les répercussions des infections par le VRS, notamment la morbidité et la mortalité, il est important de reconnaître que les cliniciens en soins primaires doivent être en mesure de repérer les personnes à risque d’infection par le VRS, de les informer efficacement sur les répercussions potentielles de la maladie et de déterminer les stratégies permettant de réduire le risque.
Références
Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023;21(11):734-749. doi:10.1038/s41579-023-00919-w
Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 15(3). doi:10.7759/cureus.36342
Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus—a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331-379. doi:10.1007/s12016-013-8368-9
Canadian Paediatric Society. Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age. Available from: https://cps.ca/en/documents/position/bronchiolitis [Accessed October 17, 2023]
NACI. Respiratory syncytial virus (RSV): Canadian Immunization Guide. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunizationguide-part-4-active-vaccines/respiratory-syncytial-virus.html [Published online March 28, 2023, Accessed October 18, 2023]
Surie D, Yuengling KA, DeCuir J, Zhu, Y, Gaglani M, Ginde AA, et al. Disease severity of respiratory syncytial virus compared with COVID-19 and influenza among hospitalized adults aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023. MMWR Morb Mortal Wkly Rep. 2023;72(40):1083-1088. doi:10.15585/mmwr.mm7240a2
Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol. 2018;71(14):1574-1583. doi:10.1016/j.jacc.2018.02.013
Juhn YJ, Wi CI, Takahashi PY, Ryu E, King KS, Hickman JA, et al. Incidence of respiratory syncytial virus infection in older adults before and during the COVID-19 Pandemic. JAMA Netw Open. 2023;6(1). doi:10.1001/jamanetworkopen.2022.50634
Hamilton MA, Liu Y, Calzavara A, Sundaram ME, Djebli M, Darvin D, et al. Predictors of all-cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS-CoV-2. Influenza Other Respir Viruses. 2022;16(6):1072-1081. doi:10.1111/irv.13004
Haber N. Respiratory syncytial virus infection in elderly adults. Med Mal Infect. 2018;48(6):377-382. doi:10.1016/j.medmal.2018.01.008
Branche AR, Saiman L, Walsh EE, Falsey AR, Jia H, Barrett A, et al. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Influenza Other Respir Viruses. 2022;16(6):1151-1160. doi:10.1111/irv.13043
Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801. doi:10.15585/mmwr.mm7229a4
Food and Drug Administration. ABRYSVOTM Product Information. Available from: https://www.fda.gov/media/168889/download [Published online August 2023, Accessed December 12, 2023]
AREXVY® Product Monograph. GlaxoSmithKline, Canada. Available from: https://pdf.hres.ca/dpd_pm/00071904.PDF [Published online August 4, 2023, Accessed December 12, 2023]
Center for Disease Control and Prevention. Healthcare Providers: RSV Vaccination for Adults 60 Years of Age and Over. Available from: https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html [Published online October 27, 2023, Accessed December 12, 2023]
Kampmann B, Madhi SA, Munjal I, Simoes EAF, Pahud BA, Llapur C, et al. Bivalent prefusion f vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-1464. doi:10.1056/NEJMoa2216480
Centers for Disease Control and Prevention. Healthcare Providers: RSV Vaccination for Pregnant People. Available from: https://www.cdc.gov/vaccines/vpd/rsv/hcp/pregnant-people.html [Published September 29, 2023, Accessed October 3, 2023]
Sun M, Lai H, Na F, Li S, Qiu X, Tian, J, et al. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis. JAMA Netw Open. 2023;6(2). doi:10.1001/jamanetworkopen.2023.0023
Canada’s Drug and Health Technology Agency. CADTH Health Technology Review: Nirsevimab (Beyfortus). Available from: https://www.cadth.ca/sites/default/files/hta-he/HC0059%20Nirsevimab%20for%20RSV%20prophylaxis-secured.pdf [Accessed October 18, 2023]
SYNAGIS® Product Monograph. AstraZeneca Canada, Inc. Available from: https://www.astrazeneca.com/content/dam/az-ca/downloads/productinformation/synagis-product-monograph-en.pdf [Date of Revision February 24, 2022, Accessed October 18, 2023]
BEYFORTUS™ Product Monograph. AstraZeneca Canada Inc. Available from: https://pdf.hres.ca/dpd_pm/00070439.PDF [Date of Initial Authorization: April 19, 2023, Accessed October 18, 2023]
Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sanchez, PJ, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920-925. doi:10.15585/mmwr.mm7234a4
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian Primary Care Today 2024
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
